Gene therapy for arthritis--where do we stand?
The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that such therapy is more advantageous for patients from the therapeutic and safety points of view. Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments.
Chernajovsky
Yuti
Y
William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London, UK. y.chernajovsky@qmul.ac.uk
D015535:Arthritis, Psoriatic / Q000235:genetics / Q000628:therapy*; D001172:Arthritis, Rheumatoid / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy / Q000191:economics / Q000639:trends*; D006801:Humans; D025241:Spondylarthritis / Q000235:genetics / Q000628:therapy*